Skip to main content
Equibles
PETV logo

PETV · PetVivo Holdings, Inc. · Metrics

Track PETV — free

Use PETV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PETV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.57 At close · Apr 9
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. There can be no assurance that the Company will be successful in achieving profitable operations, securing additional financing on acceptable terms, or successfully implementing its business plan. Accordingly, management has concluded that substantial doubt about the Company's ability to continue as a going concern is not alleviated.”
View the 10-Q filed Aug 14, 2026
Market Cap
$26.57M
Shares
37.95M
Volume · Apr 9 405.5K Avg daily vol (3M) 55.11K

PETV metrics

57 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.57
Market cap
$26.57M

Price action

20 metrics
Price change (1W)
-44.1%
Price change (30D)
—
Price change (3M)
-50.9%
Price change (6M)
-73.9%
Price change (YTD)
-46.2%
Price change (1Y)
-80.5%
Trailing year
Price change (5Y)
—
52-week high
$2.92
52-week low
$0.57
Change from 52-week high
-80.5%
Change from 52-week low
+0.0%
Annualized volatility
104.8%
Annualized volatility (3M)
106.9%
Beta
—
RSI (14D)
20.0
Price vs SMA 50
-48.8%
Price vs SMA 200
-61.4%
Avg volume (3M)
55,106
Relative volume
7.4
Average dollar volume
$58,525

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
37.95M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
22.5×
reciprocal yield 4.4%
P / book
19.6
reciprocal yield 5.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-36.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-03-31

Profitability

9 metrics
Gross margin
67.0%
Operating margin
-747.0%
Trailing 12 months
Net margin
-827.3%
Gross profit (TTM)
$791,342
Operating profit (TTM)
−$8.83M
Net income (TTM)
−$9.78M
Trailing 12 months
Diluted EPS (TTM)
$-0.33
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.06

Growth

11 metrics
Revenue growth YoY
+13.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.18M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+52.5%
Year over year · more shares
Revenue CAGR (3Y)
+7.6%
Revenue CAGR (5Y)
+146.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-720.9%
Return on assets
-366.2%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
−$8.30M
Free cash flow (TTM)
—
Quick ratio
0.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$28,891
Total assets
$2.67M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$5.44M
Capital expenditures (TTM)
—
R&D (TTM)
$1.31M
SG&A (TTM)
—
Stock compensation (TTM)
$2.21M
R&D / revenue
110.7%
Stock compensation / revenue
186.8%

Ownership (13F)

3 metrics
13F filers
1
13F filer change QoQ
+1
Institutional ownership
0.1%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
$40,022
Insider-sentiment score
80 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1512922 CUSIP 716817408 Visit website Investor relations